StockData

Upstream Bio vs Vistagen Therapeutics

UPB and VTGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How UPB and VTGN compare

Upstream Bio is the larger company, worth 19 times as much as Vistagen Therapeutics ($152M against $8.0M).

Vistagen Therapeutics keeps more of each dollar of sales as profit, with a net margin of −2475% compared with −5712% at Upstream Bio.

Vistagen Therapeutics scores higher on the StockData Score (9 against 8 for Upstream Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricUPBVTGN
Size and price
Market cap$152M$8.0M
Share price$2.78$0.180
Change, 1 year−88.3%−95.6%
Change, 5 years–−99.7%
Beta (5Y)1.281.31
Employees7541
StockData Score
Total score89 (better)
Valuation score13 (better)
Growth score00
Performance score11
Health score6 (better)5
Dividend score00
Valuation
P/S53.1×3.4× (better)
P/B0.7×0.5× (better)
Fair value–$0.660
Margin of safety–72.7%
Growth
Revenue growth (TTM)2.5%–
Revenue growth, 5Y average–3.1%
Profitability
Operating margin−6116%−2542% (better)
Net margin−5712%−2475% (better)
Return on equity−53.5% (better)−145%
Return on invested capital−846%–
Financial health
Debt / equity0.000.00
Current ratio20.45 (better)2.64
Altman Z-score3.80 (better)−37.10
Piotroski F-score12 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions92.3%26.5%
Held by insiders8.6%0.52%
Insider net buying, 12 months−$105K–
Short interest, % of float7.1%5.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.